[go: up one dir, main page]

DE60332363D1 - Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen - Google Patents

Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen

Info

Publication number
DE60332363D1
DE60332363D1 DE60332363T DE60332363T DE60332363D1 DE 60332363 D1 DE60332363 D1 DE 60332363D1 DE 60332363 T DE60332363 T DE 60332363T DE 60332363 T DE60332363 T DE 60332363T DE 60332363 D1 DE60332363 D1 DE 60332363D1
Authority
DE
Germany
Prior art keywords
hsp
cancer
dosage unit
unit form
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60332363T
Other languages
English (en)
Inventor
Martin E Gleave
Palma Rocchi
Maxim Signaevsky
Eliana Beraldi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Application granted granted Critical
Publication of DE60332363D1 publication Critical patent/DE60332363D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60332363T 2002-10-02 2003-10-02 Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen Expired - Lifetime DE60332363D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41585902P 2002-10-02 2002-10-02
US46395203P 2003-04-18 2003-04-18
PCT/CA2003/001588 WO2004030660A2 (en) 2002-10-02 2003-10-02 Compositions for treatment of prostate and other cancers

Publications (1)

Publication Number Publication Date
DE60332363D1 true DE60332363D1 (de) 2010-06-10

Family

ID=32073392

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60332363T Expired - Lifetime DE60332363D1 (de) 2002-10-02 2003-10-02 Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen

Country Status (17)

Country Link
US (8) US7101991B2 (de)
EP (2) EP1545561B1 (de)
JP (2) JP5127138B2 (de)
KR (1) KR101142080B1 (de)
CN (1) CN1703229B (de)
AT (1) ATE465743T1 (de)
AU (1) AU2003278028B2 (de)
CA (1) CA2498026C (de)
DE (1) DE60332363D1 (de)
DK (1) DK1545561T3 (de)
ES (1) ES2345330T3 (de)
IL (1) IL167621A (de)
MX (1) MXPA05003551A (de)
NO (2) NO338310B1 (de)
NZ (1) NZ538841A (de)
WO (1) WO2004030660A2 (de)
ZA (1) ZA200502603B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332363D1 (de) 2002-10-02 2010-06-10 Univ British Columbia Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen
US20060188508A1 (en) * 2005-02-17 2006-08-24 Cohen Stanley N Methods and compositions for modulating angiogenesis
US20090264502A1 (en) * 2005-08-25 2009-10-22 Bennett C Frank Compositions and their uses directed to hsp27
US8273867B2 (en) * 2006-02-10 2012-09-25 The Regents Of The University Of California Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS
US8242258B2 (en) * 2006-12-03 2012-08-14 Agilent Technologies, Inc. Protecting groups for RNA synthesis
WO2008106781A1 (en) * 2007-03-05 2008-09-12 The University Of British Columbia Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy
CA2680600A1 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
CA2656577A1 (en) * 2008-04-14 2009-10-14 The University Of British Columbia Method for evaluation of a cancer
BRPI0914123A2 (pt) * 2008-07-02 2015-10-20 Enzon Pharmaceuticals Inc antagonistas de rna que alvejam hsp27
NZ589262A (en) * 2008-07-18 2012-05-25 Oncogenex Technologies Inc Antisense formulation
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
KR101217866B1 (ko) * 2010-08-18 2013-01-03 한국원자력의학원 혈관신생 억제용 약학 조성물 및 혈관신생 억제용 활성물질을 스크리닝하는 방법
DE102010056610A1 (de) * 2010-12-31 2012-07-05 Volker A. Erdmann Pharmazeutische Zusammensetzung enthaltend L-DNA
JP5658696B2 (ja) * 2011-02-25 2015-01-28 株式会社ファンケル 皮膚のストレス蓄積度の評価方法
CA2747509C (en) 2011-05-12 2017-07-18 Oncogenex Technologies Inc. Treatment of pulmonary and pleural fibrosis using hsp27 inhibitors
EP2809325A4 (de) * 2012-02-02 2015-04-01 Univ British Columbia Kombinationstherapie gegen krebs mit einem hsp27-inhibitor und egfr-tyrosinkinasehmmern oder antifolaten
GB201204785D0 (en) 2012-03-19 2012-05-02 Queen Mary & Westfield College Method for determining prognosis of prostate cancer in a subject
KR101374585B1 (ko) * 2012-05-02 2014-03-17 연세대학교 산학협력단 ＨＳＰ２７ 발현을 억제하는 ｓｈＲＮＡ
JP2015529073A (ja) 2012-08-20 2015-10-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生物可逆性基を有するポリヌクレオチド
WO2016016268A1 (de) 2014-07-28 2016-02-04 Technische Universität Dresden Thymin- und chinazolin-dion-derivate zur hemmung von hsp27
JP7039470B2 (ja) * 2015-11-30 2022-03-22 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア がんの治療において治療薬として使用するための、モノカルボン酸トランスポーター４（ｍｃｔ４）アンチセンスオリゴヌクレオチド（ａｓｏ）阻害剤
EP3678680A4 (de) 2017-09-05 2021-12-01 Regeneron Pharmaceuticals, Inc. Freisetzung eines geneditierungssystems mit einem einzigen retroviralen partikel und verfahren zur erzeugung und verwendung

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840708A (en) * 1992-12-14 1998-11-24 Allegheny University Of The Health Sciences Administration of oligonucleotides antisense to dopamine receptor MRNA for diagnosis and treatment of Neurological pathologies
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
JPH09176011A (ja) * 1995-12-27 1997-07-08 Kureha Chem Ind Co Ltd Ｈｓｐ２７ファミリーに属するタンパク質のフラボノイド含有合成抑制剤
US20060008448A1 (en) * 1996-06-11 2006-01-12 Minzhen Xu Inhibition of li expression in mammalian cells
JPH107559A (ja) 1996-06-18 1998-01-13 Kureha Chem Ind Co Ltd Ｈｓｐ２７ファミリーに属するタンパク質のベルベリン誘導体含有合成抑制剤
US5962262A (en) 1997-07-25 1999-10-05 Incyte Pharmaceuticals, Inc. Human heat shock 27 like protein
US6703228B1 (en) 1998-09-25 2004-03-09 Massachusetts Institute Of Technology Methods and products related to genotyping and DNA analysis
US5998148A (en) * 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
WO2001005435A2 (en) 1999-07-19 2001-01-25 The University Of British Columbia Antisense therapy for hormone-regulated tumors
WO2001070976A2 (en) * 2000-03-21 2001-09-27 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
JP2005506836A (ja) * 2001-08-23 2005-03-10 アリゾナ・ボード・オブ・リージェンツ 平滑筋治療用薬剤および方法
DE60332363D1 (de) 2002-10-02 2010-06-10 Univ British Columbia Oligonucleotide zur behandlung von prostatakrebs und anderen krebserkrankungen
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20090264502A1 (en) * 2005-08-25 2009-10-22 Bennett C Frank Compositions and their uses directed to hsp27
WO2008106781A1 (en) 2007-03-05 2008-09-12 The University Of British Columbia Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy

Also Published As

Publication number Publication date
CA2498026A1 (en) 2004-04-15
US20160326527A1 (en) 2016-11-10
EP1545561B1 (de) 2010-04-28
US20060276424A1 (en) 2006-12-07
ES2345330T3 (es) 2010-09-21
JP2010215669A (ja) 2010-09-30
EP2216029A3 (de) 2010-12-22
US7550580B2 (en) 2009-06-23
US8772470B1 (en) 2014-07-08
US7723312B2 (en) 2010-05-25
ZA200502603B (en) 2006-06-28
US9404109B2 (en) 2016-08-02
KR101142080B1 (ko) 2012-05-03
US20060040886A1 (en) 2006-02-23
JP2006503904A (ja) 2006-02-02
US7101991B2 (en) 2006-09-05
AU2003278028B2 (en) 2008-12-18
WO2004030660A3 (en) 2004-06-10
NO20160655A1 (no) 2016-04-20
NO338310B1 (no) 2016-08-08
KR20050050111A (ko) 2005-05-27
CN1703229A (zh) 2005-11-30
CN1703229B (zh) 2011-01-05
US20040127441A1 (en) 2004-07-01
US7847091B2 (en) 2010-12-07
NZ538841A (en) 2006-10-27
ATE465743T1 (de) 2010-05-15
EP2216029A2 (de) 2010-08-11
US9580712B2 (en) 2017-02-28
AU2003278028A1 (en) 2004-04-23
CA2498026C (en) 2015-06-30
US20140315978A1 (en) 2014-10-23
NO20052055L (no) 2005-06-23
US20090221678A1 (en) 2009-09-03
MXPA05003551A (es) 2005-10-19
DK1545561T3 (da) 2010-08-02
US20150232843A1 (en) 2015-08-20
US9085769B2 (en) 2015-07-21
JP5237996B2 (ja) 2013-07-17
EP1545561A2 (de) 2005-06-29
IL167621A (en) 2011-11-30
WO2004030660A2 (en) 2004-04-15
JP5127138B2 (ja) 2013-01-23

Similar Documents

Publication Publication Date Title
NO20160655A1 (no) Sammensetninger og fremgangsmåter for behandling av prostata- og andre cancere
EP2102343B1 (de) Dbait und eigenständige anwendungen davon
EP1765362A4 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
CY1108870T1 (el) Αντιπαραλληλα ολιγονουκλεοτιδια (odn) κατα της smad7 και χρησεις στον ιατρικο τομεα τους
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
SG161307A1 (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
IL160015A0 (en) Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
JP2006503904A5 (de)
JP2004537500A5 (de)
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
ATE491715T1 (de) Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
EA200501456A1 (ru) Торий- 227 для применения в радиотерапии заболевания мягких тканей
BRPI0414812A (pt) método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
ITMI20030860A1 (it) Metodo per l'inibizione selettiva del gene n-myc
BR0005318A (pt) Utilização de inibidores de secreção da apo b/mtp e agentes antiobesidade
MA27474A1 (fr) Vaccin
EP1827459A4 (de) Therapeutische antisense-oligonucleotid-zusammensetzung zur behandlung von entzündlicher darmerkrankung
DE60333747D1 (de) Dna-enzym zur hemmung von plasminogenaktivator-inhibitor-1
WO2003066806A3 (en) Therapeutic use of aziridino compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition